Arcutis Biotherapeutics, Inc.
Symbol: ARQT
NASDAQ
7.99
USDMarkedspris i dag
-2.8257
P/E-forhold
0.0000
PEG Ratio
923.04M
MRK Cap
- 0.00%
DIV Udbytte
Arcutis Biotherapeutics, Inc. (ARQT) Årsregnskaber
Balance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1100.97 | 272.8 | 409.6 | 387.1 | |||||||
balance-sheet.row.short-term-investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.net-receivables | 75.2 | 25.8 | 8.5 | 0.4 | |||||||
balance-sheet.row.inventory | 46.07 | 13.1 | 7.5 | 1.2 | |||||||
balance-sheet.row.other-current-assets | 63.5 | 18.7 | 10.6 | 14.2 | |||||||
balance-sheet.row.total-current-assets | 1288.52 | 330.4 | 437.4 | 402.8 | |||||||
balance-sheet.row.property-plant-equipment-net | 17.21 | 3.9 | 4.6 | 5.3 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 26.88 | 6.4 | 7.2 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 1.87 | 0.6 | 0.1 | 0.1 | |||||||
balance-sheet.row.total-non-current-assets | 45.95 | 10.9 | 11.9 | 5.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.account-payables | 54.81 | 12 | 8.8 | 7.4 | |||||||
balance-sheet.row.short-term-debt | 2.82 | 0.7 | 0.7 | 0.4 | |||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.long-term-debt-total | 812.38 | 201.8 | 201.9 | 77.1 | |||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 104.61 | 33.9 | 28.3 | 25.5 | |||||||
balance-sheet.row.total-non-current-liabilities | 816.61 | 206 | 201.9 | 77.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 16.73 | 3.4 | 4.8 | 5.2 | |||||||
balance-sheet.row.total-liab | 978.85 | 252.7 | 239.7 | 110.5 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||
balance-sheet.row.retained-earnings | -3568.24 | -981.9 | -719.8 | -408.3 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.89 | 0 | -1.1 | -0.3 | |||||||
balance-sheet.row.other-total-stockholders-equity | 3924.73 | 1070.6 | 930.4 | 706.2 | |||||||
balance-sheet.row.total-stockholders-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1334.47 | 341.4 | 449.3 | 408.2 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 355.62 | 88.7 | 209.6 | 297.7 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 1334.47 | - | - | - | |||||||
Total Investments | 717.66 | 183.5 | 355.9 | 290.6 | |||||||
balance-sheet.row.total-debt | 818.58 | 205.9 | 202.5 | 77.6 | |||||||
balance-sheet.row.net-debt | 435.26 | 116.6 | 148.9 | -18.9 |
Pengestrømsopgørelse
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -262.14 | -262.1 | -311.5 | -206.4 | |||||||
cash-flows.row.depreciation-and-amortization | 1.52 | 1.9 | 0.9 | 0.5 | |||||||
cash-flows.row.deferred-income-tax | -19.69 | 19.8 | 0 | 3.5 | |||||||
cash-flows.row.stock-based-compensation | 38.81 | 38.8 | 32.7 | 23.9 | |||||||
cash-flows.row.change-in-working-capital | -23.5 | -23.5 | -10.2 | 3.6 | |||||||
cash-flows.row.account-receivables | -17.35 | -17.3 | -8.5 | 0 | |||||||
cash-flows.row.inventory | -5.62 | -5.6 | -7.5 | 0 | |||||||
cash-flows.row.account-payables | 3.15 | 3.2 | 1.6 | 0.2 | |||||||
cash-flows.row.other-working-capital | -3.68 | -3.7 | 4.2 | 3.4 | |||||||
cash-flows.row.other-non-cash-items | 17.94 | -21.9 | 30.3 | 0.3 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | -247.06 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.acquisitions-net | -180.66 | 0 | 22.9 | 75 | |||||||
cash-flows.row.purchases-of-investments | -225.84 | -225.8 | -415.4 | -292.5 | |||||||
cash-flows.row.sales-maturities-of-investments | 406.5 | 406.5 | 351.5 | 217.6 | |||||||
cash-flows.row.other-investing-activites | 180.66 | 0 | -22.9 | -75 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 180.23 | 180.2 | -87.2 | -76 | |||||||
cash-flows.row.debt-repayment | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.common-stock-issued | 100.26 | 101.3 | 176 | 207.5 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 12.5 | 0.8 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | -122.8 | -72.3 | |||||||
cash-flows.row.other-financing-activites | 101.32 | 5.6 | 358.9 | 218.3 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 101.32 | 101.3 | 301.8 | 281.9 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.05 | -0.1 | 0 | 0 | |||||||
cash-flows.row.net-change-in-cash | 34.45 | 34.4 | -43.1 | 31.4 | |||||||
cash-flows.row.cash-at-end-of-period | 386.09 | 89.3 | 54.9 | 98 | |||||||
cash-flows.row.cash-at-beginning-of-period | 351.64 | 54.9 | 98 | 66.6 | |||||||
cash-flows.row.operating-cash-flow | -247.06 | -247.1 | -257.7 | -174.6 | |||||||
cash-flows.row.capital-expenditure | -0.43 | -0.4 | -23.3 | -1 | |||||||
cash-flows.row.free-cash-flow | -247.49 | -247.5 | -281 | -175.6 |
Resultatopgørelse række
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 59.61 | 59.6 | 3.7 | 0 | |||||||
income-statement-row.row.cost-of-revenue | 5.18 | 6.1 | 0.8 | 0.8 | |||||||
income-statement-row.row.gross-profit | 54.42 | 53.5 | 2.9 | -0.8 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 110.58 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 235.81 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.other-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.operating-expenses | 295.52 | 294.6 | 304.6 | 206.5 | |||||||
income-statement-row.row.cost-and-expenses | 300.71 | 300.7 | 305.3 | 206.5 | |||||||
income-statement-row.row.interest-income | 12.9 | 0 | 9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.selling-and-marketing-expenses | -50.87 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 11.72 | 11.8 | 5.8 | 0.2 | |||||||
income-statement-row.row.total-operating-expenses | -3.08 | -17.9 | -9.8 | 0.2 | |||||||
income-statement-row.row.interest-expense | 29.71 | 29.7 | 15.7 | 0 | |||||||
income-statement-row.row.depreciation-and-amortization | 6.7 | 1.9 | 5.8 | 0.5 | |||||||
income-statement-row.row.ebitda-caps | -231.67 | - | - | - | |||||||
income-statement-row.row.operating-income | -241.1 | -241.1 | -301.6 | -206.5 | |||||||
income-statement-row.row.income-before-tax | -259.09 | -259 | -311.5 | -206.4 | |||||||
income-statement-row.row.income-tax-expense | 12.77 | 3.1 | 9.8 | -0.5 | |||||||
income-statement-row.row.net-income | -261.78 | -262.1 | -321.3 | -205.9 |
Ofte stillede spørgsmål
Hvad er Arcutis Biotherapeutics, Inc. (ARQT) samlede aktiver?
Arcutis Biotherapeutics, Inc. (ARQT) samlede aktiver er 341365000.000.
Hvad er virksomhedens årlige omsætning?
Den årlige omsætning er 51635000.000.
Hvad er virksomhedens profitmargin?
Virksomhedens profitmargin er 0.913.
Hvad er virksomhedens frie pengestrøm?
Det frie cash flow er -2.673.
Hvad er virksomhedens nettoprofitmargin?
Nettofortjenstmargenen er -4.392.
Hvad er firmaets samlede omsætning?
Den samlede omsætning er -4.045.
Hvad er Arcutis Biotherapeutics, Inc. (ARQT) nettoresultat (nettoindkomst)?
Nettoresultatet (nettoindkomsten) er -262140000.000.
Hvad er virksomhedens samlede gæld?
Den samlede gæld er 205916000.000.
Hvad er tallet for driftsudgifter?
Driftsudgifterne er 294589000.000.
Hvad er firmaets likviditet?
Virksomhedens likviditet er 89323000.000.